Imagine a dark blue pigment produced by an opportunistic bacterium entering the human body and killing immune cells one by one—cells that should be serving as the body's first line of defense. This is what pyocyanin, a toxin produced by Pseudomonas aeruginosa, can do. The bacterium has long been recognized as a serious threat to patients with weakened immune systems. Now, research from the Department of Oral Biology, Faculty of Dentistry, Universitas Gadjah Mada, has revealed an unexpected finding: antibodies extracted from chicken egg yolks can inhibit immune-cell death triggered by this toxin.
When an “Opportunistic” Bacterium Becomes a Serious Threat
Pseudomonas aeruginosa is no ordinary bacterium. It is found virtually everywhere, from soil to water, but becomes particularly dangerous when it infects vulnerable patients. In hospitals, it is a major cause of nosocomial infections involving the urinary tract, respiratory tract, and central nervous system. Moreover, the presence of P. aeruginosa in dental pulp canals and periapical lesions can contribute to endodontic treatment failure, making it highly relevant to dentistry.
What makes this bacterium even more difficult to control is its ability to develop resistance to multiple antibiotics. This has encouraged researchers to seek alternative approaches—not simply to eliminate the bacterium directly, but to neutralize one of its weapons: pyocyanin.
Pyocyanin, or PCN, is a redox-active blue pigment belonging to the tricyclic phenazine family. It suppresses the functions of B cells, T cells, and macrophages while inducing neutrophil death. In other words, PCN effectively weakens the body's immune defenses from within.
Chicken Eggs as a Source of Antibodies
Prof. drg. Heni Susilowati, M.Kes., Ph.D., PBO, together with researchers from the Department of Oral Biology at FKG UGM, posed a seemingly simple but complex question: could antibodies specifically targeting PCN protect immune cells from the toxin's deadly effects?
To answer this question, the researchers adopted a relatively uncommon approach in this context, using immunoglobulin Y (IgY), an antibody found in the egg yolks of birds. Five three-month-old Leghorn chickens were immunized subcutaneously with PCN mixed with Freund's adjuvant, followed by two booster doses at two-week intervals. Eggs were collected one week after the final immunization, and IgY was isolated directly from the yolks.
Why chickens? Because the avian immune system produces IgY in response to injected antigens, and these antibodies accumulate in egg yolks in sufficiently large quantities to be harvested without invasive procedures on the animals. This also makes the approach more ethical than repeated blood-serum collection.
The presence of anti-PCN antibodies in the IgY isolates was confirmed using two methods: an agarose gel precipitation test (AGPT), which demonstrated clear precipitation lines, and ELISA, which quantitatively measured antibody concentrations. The ELISA results showed that the first batch contained 8.95 μg/μL of specific IgY, considerably higher than the second batch, which contained only 3.02 μg/μL.
Cells Surviving the Toxin Attack
The next stage involved direct testing on cells. The researchers used Raji cells, a human B-cell lymphoma line, and exposed them to various concentrations of PCN. The results were consistent with previous findings: PCN killed Raji cells in a dose-dependent manner—the higher the concentration, the greater the number of cells that died.
Then came the critical moment. When Raji cells exposed to PCN were subsequently treated with anti-PCN IgY at concentrations of 28.19 μg/mL or higher, cell survival increased significantly compared with cells treated with PCN alone (p < 0.05). Under a microscope using acridine orange/ethidium bromide staining, cells treated with the combination of PCN and IgY showed substantially more green staining, indicating viable cells, compared with PCN-only cells, which were predominantly orange-red.
“Anti-PCN IgY antibodies specific to PCN significantly reduce the ability of this virulence [factor] to induce Raji cell death in a dose-dependent fashion.” — Prof. drg. Heni Susilowati, M.Kes., Ph.D., PBO, et al., F1000Research, 2019
The precise mechanism has not yet been fully established. The researchers hypothesized that the PCN-IgY complex fails to activate the caspase-3 pathway inside Raji cells, which is known to be a major trigger of PCN-induced cell death. However, this hypothesis still requires further confirmation.
From the Laboratory to Future Therapy
Funded by Indonesia's Ministry of Research, Technology, and Higher Education, the study opens up an intriguing possibility. IgY-based immunotherapy targeting P. aeruginosa has previously been shown to be effective in preventing bacterial colonization in patients with cystic fibrosis through both active and passive immunization. This study expands that concept by demonstrating that IgY antibodies may not only act against the bacterium itself but may also neutralize a specific toxin released by the bacterium.
Of course, the gap between laboratory findings and clinical application remains substantial. Questions about how PCN enters host cells, which cell-surface antigens interact with IgY, and what immunotherapy protocol would be appropriate for humans all remain unanswered. But that is precisely what makes research like this compelling: it is not the endpoint, but the starting point for a deeper series of questions.
As antibiotics increasingly lose their effectiveness against bacteria that continue to evolve, perhaps the next answer may be hidden in one of the most unexpected places—inside the yolk of a chicken egg.
Source DOI: https://doi.org/10.12688/f1000research.19327.1
Authors: Anny Anggraini; drg. Achmad Zam Zam Aghasy, M.Kes.
Photo: Pexels